Piscataway, NJ, February 12, 2024– Camber Pharmaceuticals is pleased to announce the addition of Paliperidone Extended-Release Tablets to its current portfolio.
Paliperidone Extended- Release Tablets are an atypical antipsychotic agent indicated for treatment of schizophrenia, treatment of schizoaffective disorder as monotherapy, and as an adjunct to mood stabilizers and/or antidepressants.
Paliperidone Extended- Release Tablets are available in 1.5, 3, 6, and 9 mg strengths in 30 count bottles.
To find out more about Paliperidone Extended- Release Tablets please visit www.camberpharma.com/paliperidone
Recent articles
- New to Camber’s Portfolio: Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets
- Camber Pharmaceuticals Honored as Second Merit Finalist at 2026 DIANA Awards
- Camber Launches Nitazoxanide Tablets
- Cisatracurium Besylate Injection, USP Added to Camber’s Portfolio
- Camber Welcomes Summer 2026 Intern Class
- Camber Launches 5 Generics in May






